News
A study of IDIBELL and IDIBGI evaluates the efficacy of an anti-tumour drug against obesity
The drug inhibits the S6K1 protein, which is essential for the development of new fat cells, responsible for the disproportionate growth of fat deposits in obese people.
A generic antiviral could improve the life expectancy of patients with a rare disease without a cure
IDIBELL and Hospital de Bellvitge are studying the efficacy of Efavirenz, an antiretroviral against HIV, for the treatment of Niemann Pick type C in a clinical trial.
Two out of Three Women Between 30 and 49 Years of Age Have Never Been Screened for Cervical Cancer
A new study produces comparable estimates of screening coverage for 202 countries and territories
AtG Therapeutics completes a seed financing round raising more than half a million euros
The spin-off that emerged from IDIBELL and the Catalan Institute of Oncology is developing new therapeutic alternatives for advanced cancers and a screening system for these patients.
White adipose tissue is the most vulnerable to metabolic changes caused by obesity
The study, based on an animal experimental model, shows that when physiological stress exceeds the capacity of white adipose tissue to respond, it reaches a point of no return where it loses its metabolic plasticity.
A model that improves screening of colorectal cancer has been developed
The study, led by researchers from IDIBELL, ICO and Hospital Clínic-IDIBAPS, analyzes the genetic variants associated with the risk of developing the cancer and should make it possible to reduce the number of unnecessary colonoscopies.
A Josep Maria Aran’s project financed by CaixaResearch Validate grants
These grants promote the creation of new products and companies in life sciences and health, as well as help transfer the research results to society and the market.
The Clinical Research and Clinical Trials Unit obtains the ISO 9001:2015 recertification
The IDIBELL Clinical Research and Clinical Trials Unit (UICEC), managed by the HUB’s Clinical Pharmacology service and led by the head of this service, Dr. Pilar Hereu, achieved recertification of the quality management system.
The association for epilepsy “If I can, you too #epilep” donates 10,000 euros to research
The funds will be directed to the IDIBELL and Bellvitge Hospital research group in Neurological Diseases and Neurogenetics.